SHINE 2Europe is partner in Horizon Europe project RadioVal, to validate an artificial intelligence solution for breast cancer treatment planning

RadioVal is the first major multi-centre, multi-continental and multi-disciplinary project to clinically validate an artificial intelligence solution for the prediction of patient-specific response to neoadjuvant chemotherapy in breast cancer, in eight clinical centers across Europe, South America, North Africa and Eurasia.

RadioVal | International Clinical Validation of Radiomics Artificial Intelligence for Breast Cancer Treatment Planning is a project funded under Horizon Europe, with a consortium of 16 partners led by the University of Barcelona, and with the Portuguese participation of SHINE 2Europe, which will lead the work package on social innovation.

RadioVal will be the first major multicenter, multi-continental and multifaceted clinical validation project for the estimation of radiomic-oriented adjuvant chemotherapy in the response to breast cancer, in eight clinical centers in five EU countries (Sweden, Austria, Spain, Poland, Croatia) and three countries from other regions of the world – South America (Argentina), Africa (Egypt) and Eurasia (Turkey). One of the results of the project will be a methodological structure to evaluate the Artificial Intelligence tools that will be used in the field of radiomics, according to technical, clinical and ethical criteria.

SHINE 2Europe is a Portuguese SME that seeks to promote more inclusive communities for all citizens, through the development of pioneering research and social innovation projects, with a particular focus on ethics and multidisciplinary participation.

Carina Dantas, CEO of SHINE stated “RadioVal is a unique opportunity to involve citizens, professionals, patients  and  public decision-makers discussing the fears, opportunities and challenges of using Artificial Intelligence in breast cancer treatment decision-making. SHINE is proud and extremely committed to its responsibilities in this unique project.”

In RadioVal, SHINE will be leading Work Package 1 – Multi-stakeholder engagement and social Innovation, developing the methodology to involve citizens, professionals, patients, public authorities and other relevant actors in the evaluation and implementation of radiomics and Artificial Intelligence tools in breast cancer treatment. SHINE will also be leading the impact assessment process concerning the socio-ethical implications of this work, including the diversity of contexts, countries and populations.

The project begins on September 1, 2022 and the launch meeting will take place in Barcelona on September 15 and 16, with representatives of the RadioVal consortium.

The project is co-financed under horizon Europe under the topic HORIZON-HLTH-2021-DISEASE-04 and received funding of EUR 5.8 million.

Official project information at:

Official RadioVal Press Release